Impax Laboratories — Investor Presentation (May 2008)
32 slides from Impax Laboratories's investor presentation, May 15, 2008
Slide 1: Impax
CID IMPAX iia
Slide 2: Safe Harbor statement
Impax Laboratories, Inc. (IPXL.PK) "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical, these statements are forward- looking in nature and express the beliefs and expect
Slide 3: 10-K Filing Timeline 2004-2007 Audits
10-K Filing Timeline 2004 - 2007 Audits 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q - -------------2005------------- ------------------2006------------------ --------------------2007---------------------2008------ * Company estimate and there is necessarily some degree of uncertainty inherent in estimate
Slide 4: Overview
Overview Technology-based specialty pharmaceutical company More than 160 R & D experts focused on formulating products that do not infringe existing patents Generic - Concentration on First-to-File, First-to-Market opportunities Brand - 505 (b)(2) NDA Candidates focused on CNS Significant commercial
Slide 5: Patented Techniques and Know-How
Patented Techniques and Know-How United States Foreign 7 12 United States Foreign 9 40 Patents Issued Pending Applications
Slide 6: Substantial Development and Drug Delivery Capabilities
Substantial Development and Drug Delivery Capabilities Approved ANDAs Pending at FDA Under Development East 44 20 51 US Product Sales 20 51 44 115 Generic Products Approved, Pending or Under Development Targeting over $36 Billion in US Product Sales $7B $20B $9B
Slide 7: Technological Edge
Technological Edge Corepharma Ranbaxy Nostrum Mallinckrodt Dr Reddy's Sun/Taro Apotex/Torpharm KV Actavis/Abrika Barr Sandoz/Lek Teva/Ivax Watson/Andrx Mylan 3 3 3 3 3 4 5 8 9 10 12 12 12 12 15 CR Filers With at Least 3 Approvals
Slide 8: R&D Highlights: FDA Approvals
R&D Highlights Received 6 FDA approvals for 2007 - generic versions of: CORZIDE(r) 40/5mg, 80/5mg DITROPAN XL(r) 5,10mg XANAX(r) XR 0.5,1,2,3mg LOPID(r) 600mg PERSANTINE(r) 25,50,75mg BACLOFEN 10,20mg Received 3 FDA approvals for 2008 - generic versions of: MYSOLINE(r) 50,250mg PHENERGAN(r) 12.5,25m
Slide 9: R&D Highlights: Product Launches
R&D Highlights Launched 5 new products for 2007 - generic versions of: COLESTID(r) Tablets 1g URECHOLINE(r) 5,10,15,20,25mg DITROPAN XL(r) 5,10mg CORZIDE(r) 40/5mg, 80/5mg PERSANTINE(r) 25,50,75mg Launched 2 new products for 2008 - generic versions of: MYSOLINE(r) 50,250mg PHENERGAN(r) 12.5,25mg
Slide 10: Research and Development Strategy
Research and Development Strategy
Slide 11: Formulation Expertise
Formulation Expertise Applied Technology Products Branded Products CNS Products Generic Products First-to-File First-to-Market Limited Competition Candidates
Slide 12: Technology
Technology State-of-the art formulation techniques Diverse oral-solid formulation capabilities Targeting products with limited competition Controlled release projects where our substantial experience allows us to formulate around existing patents Specialty formulation projects where we focus on diff
Slide 13: Outsourced Product Development
Outsourced Product Development Complements (and leverages) internal programs Directed programs 4 offshore companies 1 domestic company 12 projects outsourced 5 already submitted and 4 approved
Slide 14: Substantial and Growing Manufacturing Capacity
Substantial and Growing Manufacturing Capacity Hayward operations 1.2 billion unit annual capacity Taiwan plant underway Initial phase - 50% increase Fully approved and operational early 2010
Slide 15: Taiwan Construction
Taiwan Construction $25 million capital budget All production for export to the US Will be one of only a few FDA approved dosage form plants in Asia
Slide 16: Generic Target Market
Generic Target Market CR IR 48 25 Pending Approved Underdevelopment 23 44 50 Immediate & Controlled Release Pending & Under Development ANDAs Number of Products Under Development 51 = $20B Pending 20 = $9B Approved 44 = $7B Market: US Market size in billions of US $ IR 24 = $4B CR 47 = $25B
Slide 17: Paragraph-IV Generic Products Filings
Paragraph-IV Generic Products 26 Filings Impax Project Generic of* Est. Filing Order** Initial Filing Omeprazole 10,20,40mg DR PRILOSEC(r) (AZN) 5th of 10 total 4Q99 Bupropion 100,150mg ER WELLBUTRIN(r) SR (GSK) 3rd of 5 total 2Q00 Bupropion 150mg ER ZYBAN(r) (GSK) 2nd of 4 total 2Q00 Fenofibrate 67
Slide 18: Paragraph-IV Generic Products
Paragraph-IV Generic Products Impax Project Generic of* Est. Filing Order** Initial Filing Carbidopa/Levodopa ER SINEMET(r) CR (BMS) 2nd of 4 total 4Q02 Carprofen 25,75 &100mg (Vet) RIMADYL(r) (Pfizer) 1st of 2 total 4Q02 Bupropion 200mg ER WELLBUTRIN(r) SR (GSK) 1st of 2 total 1Q03 Oxybutynin 5,10,
Slide 19: Paragraph-IV Litigation Status
Paragraph-IV Litigation Status Project Litigation Status Omeprazole 10, 20 & 40mg DR May 2007 trial court decision that Impax product infringes; patent not invalid. On appeal to the CAFC. Fexofenadine & PSE ER No trial date scheduled. Venlafaxine 37.5, 75, 150mg ER Trial scheduled July 2008. Divalpr
Slide 20: Commercial Strategy
Commercial Strategy Competitive advantages - How we are different Broad-based Approach Multiple commercial outlets in uniquely diverse categories Customer focus Product selection - provide customers with generics that are somewhat unique Equally responsive to near-term customer needs and long- term
Slide 21: Commercial Strategy: Primary Commercial Outlets
Commercial Strategy Primary Commercial Outlets: (Generic) Highly experienced generic field sales organization currently supplying ALL major U.S. generic purchasers Fully integrated internal customer service organization; including electronic commerce (EDI, electronic chargeback processing, etc.) wit
Slide 22: Commercial Strategy: Strategic Alliances
Commercial Strategy - -Strategic Alliances- Supplemental Commercial Outlets: TEVA - 12 products, 9 launched (only 22% of all 41 marketed products) DAVA - Oxycodone (OXYCONTIN(r)) 2nd Marketing period concluded Opportunistic Only if and when valuable
Slide 23: Generic Sales Capability
Generic Sales Capability 62 Partnered 14 Global and Partnered Products Number of Marketed Products (SKU's)
Slide 24: Brand Projects
Brand Projects CID IMPAX CDIMPAX yz
Slide 25: Brand Projects
Brand Projects Improved versions of marketed products Same R & D platform Clinical development Focused on CNS Smaller, more concentrated addressable market NDA Pending In Clinical Evaluation Development 1 1 2 Under Development 2 NDA Pending 1 In Clinical Evaluation 1 Product Pipeline
Slide 26: Branded Products Pipeline
Branded Products Pipeline IPX056 Under clinical evaluation Clinical study targeted completion 2008 Data analysis and NDA submission target 2009 IPX066 Clinical evaluation in 2008/2009 Replaces current formulation of Vadova(tm) Next generation Carbidopa/Levodopa product Expect to have more significan
Slide 27: Brand Marketing and Sales
Brand Marketing and Sales 66 Reps calling on targeted neurologists with CARBATROL(r) (Shire) $39 million funding through 6/2009 Physician relationships that will facilitate marketing future internal brand products with Impax
Slide 28: Significant Filing Milestones
Significant Filing Milestones *Includes amendments to two previously filed applications-not included in 2005 applications filed Filing Goal 2008: 8-10 with focus on controlled-release products 2000/ 2002 2003 2004 2005 2006 2007 2008 (YTD) Applications Filed 24 8 5 10 6 7 PPG IV filings 14 4 1 3* 1
Slide 29: Applications Filed and Approved or Pending Approved
Applications Filed and Approved or Pending Approved2 Approved2 Approved2 Approved2 Approved2 Approved2 Filed 2004 2005 2006 2007 2008 Pending Applications Filed1 2003 6 1 3 1 1 Applications Filed1 2004 4 4 See note 3 Applications Filed1 2005 9 1 4 2 2 Applications Filed1 2006 6 2 4 Applications File
Slide 30: Healthy Cash Position - Modest Debt Level
Healthy Cash Position - Modest Debt Level Q406 Q107 Q207 Q307 Q407 Q108 East 29.4 47.1 62.5 142.2 143.7 136.6 Q406 Q107 Q207 Q307 Q407 Q108 East 89.6 89.2 86.5 86.1 82.8 82.3 $ Millions Cash and Investments Long-Term Debt Note 1: Significant estimated tax payment made 4Q 2007 totaling approximately
Slide 31: Strong Management Team
Strong Management Team Larry Hsu, Ph.D., President & CEO 30 years of experience, Abbott Laboratories, co-founded Impax David Doll, EVP Commercial Operations 20+ years of experience, Merck and Teva Arthur A. Koch, Jr., SVP, CFO 30 years of experience, Strategic Diagnostics, IBAH Inc., KPMG LLC Charle
Slide 32: Strong Platform for Growth
Strong Platform for Growth Broad-based drug delivery technology Strong product portfolio "Renewable" Strong management team Brand products offer long-term growth driver
Impax Laboratories — Investor Presentation (May 2008) on 6ix